Discontinued — last reported Q4 '26
EBIT at other companies
Other financials
Where this comes from
Calculated from Immunovant, Inc.’s reported figures.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s EBIT?
- Immunovant, Inc. (IMVT) reported EBIT of -$142.64M in Q1 2026.
- How has Immunovant, Inc.'s EBIT changed year-over-year?
- Immunovant, Inc.'s EBIT decreased by 44.1% year-over-year, from -$98.98M to -$142.64M.
- What is the long-term trend for Immunovant, Inc.'s EBIT?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s EBIT has grown at a 32.3% compound annual growth rate (CAGR), from -$156.81M to -$480.06M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.